Cargando…

Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy

Gene therapy, as an emerging therapeutic approach, has shown remarkable advantages in the treatment of some major diseases. With the deepening of genomics research, people have gradually realized that the emergence and development of many diseases are related to genetic abnormalities. Therefore, nuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yongguang, Liu, Xinhua, Chen, Na, Yang, Xiaochun, Tang, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864445/
https://www.ncbi.nlm.nih.gov/pubmed/36678807
http://dx.doi.org/10.3390/pharmaceutics15010178
_version_ 1784875586431221760
author Gao, Yongguang
Liu, Xinhua
Chen, Na
Yang, Xiaochun
Tang, Fang
author_facet Gao, Yongguang
Liu, Xinhua
Chen, Na
Yang, Xiaochun
Tang, Fang
author_sort Gao, Yongguang
collection PubMed
description Gene therapy, as an emerging therapeutic approach, has shown remarkable advantages in the treatment of some major diseases. With the deepening of genomics research, people have gradually realized that the emergence and development of many diseases are related to genetic abnormalities. Therefore, nucleic acid drugs are gradually becoming a new boon in the treatment of diseases (especially tumors and genetic diseases). It is conservatively estimated that the global market of nucleic acid drugs will exceed $20 billion by 2025. They are simple in design, mature in synthesis, and have good biocompatibility. However, the shortcomings of nucleic acid, such as poor stability, low bioavailability, and poor targeting, greatly limit the clinical application of nucleic acid. Liposome nanoparticles can wrap nucleic acid drugs in internal cavities, increase the stability of nucleic acid and prolong blood circulation time, thus improving the transfection efficiency. This review focuses on the recent advances and potential applications of liposome nanoparticles modified with nucleic acid drugs (DNA, RNA, and ASO) and different chemical molecules (peptides, polymers, dendrimers, fluorescent molecules, magnetic nanoparticles, and receptor targeting molecules). The ability of liposome nanoparticles to deliver nucleic acid drugs is also discussed in detail. We hope that this review will help researchers design safer and more efficient liposome nanoparticles, and accelerate the application of nucleic acid drugs in gene therapy.
format Online
Article
Text
id pubmed-9864445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98644452023-01-22 Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy Gao, Yongguang Liu, Xinhua Chen, Na Yang, Xiaochun Tang, Fang Pharmaceutics Review Gene therapy, as an emerging therapeutic approach, has shown remarkable advantages in the treatment of some major diseases. With the deepening of genomics research, people have gradually realized that the emergence and development of many diseases are related to genetic abnormalities. Therefore, nucleic acid drugs are gradually becoming a new boon in the treatment of diseases (especially tumors and genetic diseases). It is conservatively estimated that the global market of nucleic acid drugs will exceed $20 billion by 2025. They are simple in design, mature in synthesis, and have good biocompatibility. However, the shortcomings of nucleic acid, such as poor stability, low bioavailability, and poor targeting, greatly limit the clinical application of nucleic acid. Liposome nanoparticles can wrap nucleic acid drugs in internal cavities, increase the stability of nucleic acid and prolong blood circulation time, thus improving the transfection efficiency. This review focuses on the recent advances and potential applications of liposome nanoparticles modified with nucleic acid drugs (DNA, RNA, and ASO) and different chemical molecules (peptides, polymers, dendrimers, fluorescent molecules, magnetic nanoparticles, and receptor targeting molecules). The ability of liposome nanoparticles to deliver nucleic acid drugs is also discussed in detail. We hope that this review will help researchers design safer and more efficient liposome nanoparticles, and accelerate the application of nucleic acid drugs in gene therapy. MDPI 2023-01-04 /pmc/articles/PMC9864445/ /pubmed/36678807 http://dx.doi.org/10.3390/pharmaceutics15010178 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gao, Yongguang
Liu, Xinhua
Chen, Na
Yang, Xiaochun
Tang, Fang
Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy
title Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy
title_full Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy
title_fullStr Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy
title_full_unstemmed Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy
title_short Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy
title_sort recent advance of liposome nanoparticles for nucleic acid therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864445/
https://www.ncbi.nlm.nih.gov/pubmed/36678807
http://dx.doi.org/10.3390/pharmaceutics15010178
work_keys_str_mv AT gaoyongguang recentadvanceofliposomenanoparticlesfornucleicacidtherapy
AT liuxinhua recentadvanceofliposomenanoparticlesfornucleicacidtherapy
AT chenna recentadvanceofliposomenanoparticlesfornucleicacidtherapy
AT yangxiaochun recentadvanceofliposomenanoparticlesfornucleicacidtherapy
AT tangfang recentadvanceofliposomenanoparticlesfornucleicacidtherapy